胰腺癌患者血浆k-ras基因与肿瘤标志物联合检测及其意义

目的 :了解胰腺癌患者血浆中肿瘤标志物水平和k ras基因突变情况 ,评价基因突变与肿瘤标志物联合检测对胰腺癌患者的诊断价值。方法 :收集经手术或病理确诊为胰腺恶性疾病患者 2 1例 ,ELISA检测血浆CA19 9、CA2 42、CA5 0、CEA水平 ,PCR RFLP检测k ras基因突变 ,并与 11例胰腺良性疾病患者对照。结果 :胰腺癌患者血浆中k ras基因突变率 73.7%,胰腺良性疾病k ras基因无突变。k ras基因突变检测的敏感性与特异性分别为 6 1.9%和10 0 %,血浆k ras、CA19 9、CA2 42联合检测的敏感性和特异性分别为 85 .7%和 71.9%。结论 :联合检测血浆中k ras基因与肿瘤标志物可提高胰腺癌诊断的敏感性 ,对胰腺癌筛查、诊断与鉴别诊断有一定的临床意义。

Combined k-ras Mutation and Tumor Markers Detection in the Plasma of Patients with Pancreatic Carcinoma

Purpose: To study the k-ras mutation and the lever of tumor markers in the plasma of pancreatic carcinoma, and evaluate the diagnostic value of combined k-ras mutation and tumor markers detection in pancreatic carcinoma. Methods: A total of 32 plasma samples from patients with pancreatic carcinoma and other benign pancreatic disease were collected. The lever of CA19-9?CA242?CA50?CEA was detected by ELISA, and k-ras 12 codon mutation was detected by the means of polymerase chian reaction-restriction fragment length polymorphis(PCR-RFLP). Results: k-ras mutation rate of pancreatic carcinoma in the plasma was 73.7%, compared with 0% in other benign pancreatic carcinoma. The sensitivity and specificity of k-ras mutation assay were 61.9%and 100% respectively. The sensitivety and the specificity of combined assay reached 85.7% and 71.9%. Conclution: Combined k-ras mutation and tumor markers detection could elevate the diagnostic sensitivity of pancreatic carcinoma. The result suggest that combined detection of k-ras mutation and tumor markers is helpful to screen and diagnosis pancreatic carcinoma.